285. Guidelines: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure Question #15 with Dr. Ileana Pina

Published: April 11, 2023, 1:21 a.m.

The following question refers to Section 10.1 of the\xa02022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.\xa0The question is asked by Western Michigan University medical student and CardioNerds Intern Shivani Reddy, answered first by Boston University cardiology fellow and CardioNerds Ambassador Dr. Alex Pipilas, and then by expert faculty Dr. Ileana Pina.Dr. Pina is Professor of Medicine and Quality Officer for the Cardiovascular Line at Thomas Jefferson University, Clinical Professor at Central Michigan University, and Adjunct Professor of Biostats and Epidemiology at Case Western University. She serves as Senior Fellow and Medical Officer at the Food and Drug Administration\u2019s Center for Devices and Radiological Health.The\xa0Decipher the Guidelines: 2022 AHA / ACC / HFSA Guideline for The Management of Heart Failure\xa0series was developed by the CardioNerds and created in collaboration with the American Heart Association and the Heart Failure Society of America. It was created by 30 trainees spanning college through advanced fellowship under the leadership of CardioNerds Cofounders\xa0Dr. Amit Goyal\xa0and\xa0Dr. Dan Ambinder, with mentorship from\xa0Dr. Anu Lala,\xa0Dr. Robert Mentz, and\xa0Dr. Nancy Sweitzer. We thank Dr. Judy Bezanson and Dr. Elliott Antman for tremendous guidance.Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values.\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\tQuestion #15\n\t\t\t\t\t\n\n\n\nMrs. Framingham is a 65-year-old woman who presents to her cardiologist\u2019s office for stable angina and worsening dyspnea on minimal exertion. She has a history of non-insulin dependent type 2 diabetes mellitus and hypertension. She is taking metformin, linagliptin, lisinopril, and amlodipine. Blood pressure is 119/70 mmHg. Labs are notable for a hemoglobin of 14.2 mg/dL, iron of 18 mcg/dL, ferritin 150 ug/L, transferrin saturation 15%, and normal creatine kinase. An echocardiogram shows reduced left ventricular ejection fraction of 25%. Coronary angiography shows obstructive lesions involving the proximal left anterior descending, left circumflex, and right coronary arteries. In addition to optimizing GDMT, which of the following are recommendations for changes in management?\n\n\n\n\nA\n\n\nAnticoagulation, percutaneous revascularization, and IV iron\n\n\n\n\nB\n\n\nA change in her diabetic regimen, percutaneous revascularization, and PO iron\n\n\n\n\nC\n\n\nA change in her diabetic regimen, surgical revascularization, and IV iron\n\n\n\n\nD\n\n\nA change in her diabetic regimen, medical treatment alone for CAD, and PO iron\n\n\n\n\nE\n\n\nAnticoagulation and surgical revascularization\n\n\n\n\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\tAnswer #15\n\t\t\t\t\t\n\n\n\nExplanation\n\n\nThe correct answer is C \u2013 a change in her diabetic regimen, surgical treatment and IV iron.\nMultimorbidity is common in patients with heart failure. More than 85% of patients with HF also have at least 2 additional chronic conditions, of which the most common are hypertension, ischemic heart disease, diabetes, anemia, chronic kidney disease, morbid obesity, frailty, and malnutrition. These conditions can markedly impact patients\u2019 tolerance to GDMT and can inform prognosis.\nNot only was Mrs. F found with HFrEF (most likely due to ischemic cardiomyopathy), but she also suffers from severe multi-vessel coronary artery disease, hypertension, and non-insulin dependent type 2 diabetes mellitus.\nIn addition to starting optimized GDMT for HF, specific comorbidities in the heart failure patient warrant specific treatment strategies. Mrs. Framingham would benefit from a change in her diabetic regimen, namely switching from linagliptin to an SGLT2 inhibitor (e.g., empagliflozin, dapagliflozin). In patients with HF and type 2 diabetes, the\nuse of SGLT2i is recommended for the management of hyperglycemia and to reduce HF related morbidity and mortality (Class 1, LOE A).\nFurthermore, as she has diabetes, symptomatic severe multi-vessel CAD, and LVEF\u226435%,